
Valentina Gandin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7392260/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antiproliferative activity of nickel(II), palladium(II) and zinc(II) thiosemicarbazone complexes. Inorganica Chimica Acta, 2022, 533, 120779.	2.4	8
2	Cu(I) and Cu(II) Complexes Based on Lonidamine-Conjugated Ligands Designed to Promote Synergistic Antitumor Effects. Inorganic Chemistry, 2022, 61, 4919-4937.	4.0	11
3	Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration. International Journal of Molecular Sciences, 2022, 23, 7081.	4.1	9
4	Pt(<scp>iv</scp>) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity. Dalton Transactions, 2021, 50, 4663-4672.	3.3	11
5	Easily Available, Amphiphilic Diiron Cyclopentadienyl Complexes Exhibit in Vitro Anticancer Activity in 2D and 3D Human Cancer Cells through Redox Modulation Triggered by CO Release. Chemistry - A European Journal, 2021, 27, 10169-10185.	3.3	25
6	Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?. Journal of Medicinal Chemistry, 2021, 64, 11364-11378.	6.4	30
7	Effect of chirality on the anticancer activity of Pt(<scp>ii</scp>) and Pt(<scp>iv</scp>) complexes containing 1 <i>R</i> ,2 <i>R</i> and 1 <i>S</i> ,2 <i>S</i> enantiomers of the <i>trans</i> -1,2-diamino-4-cyclohexene ligand (DACHEX), an analogue of diaminocyclohexane used in oxaliplatin. Dalton Transactions. 2021. 50. 15655-15668.	3.3	7
8	Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. Journal of Controlled Release, 2021, 340, 318-330.	9.9	8
9	In vitro antitumor activity of water-soluble copper(I) complexes with diimine and monodentate phosphine ligands. Arabian Journal of Chemistry, 2020, 13, 998-1010.	4.9	16
10	Anticancer activity, DNA binding and cell mechanistic studies of estrogen-functionalised Cu(II) complexes. Journal of Biological Inorganic Chemistry, 2020, 25, 49-60.	2.6	18
11	Antiproliferative Homoleptic and Heteroleptic Phosphino Silver(I) Complexes: Effect of Ligand Combination on Their Biological Mechanism of Action. Molecules, 2020, 25, 5484.	3.8	17
12	InÂvitro and inÂvivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target. European Journal of Medicinal Chemistry, 2020, 194, 112266.	5.5	85
13	Synthesis and Cytotoxic Activity Evaluation of New Cu(I) Complexes of Bis(pyrazol-1-yl) Acetate Ligands Functionalized with an NMDA Receptor Antagonist. International Journal of Molecular Sciences, 2020, 21, 2616.	4.1	20
14	Synthesis, Characterization and Biological Activity of Novel Cu(II) Complexes of 6-Methyl-2-Oxo-1,2-Dihydroquinoline-3-Carbaldehyde-4n-Substituted Thiosemicarbazones. Molecules, 2020, 25, 1868.	3.8	18
15	Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance. International Journal of Molecular Sciences, 2020, 21, 2325.	4.1	12
16	Expanding the Arsenal of Pt ^{IV} Anticancer Agents: Multiâ€action Pt ^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie, 2019, 131, 18386-18391.	2.0	11
17	Expanding the Arsenal of Pt ^{IV} Anticancer Agents: Multiâ€action Pt ^{IV} Anticancer Agents with Bioactive Ligands Possessing a Hydroxy Functional Group. Angewandte Chemie - International Edition, 2019, 58, 18218-18223.	13.8	47
18	Sesquiterpene rich essential oil from Nepalese Bael tree (Aegle marmelos (L.) Correa) as potential antiproliferative agent. Fìtoterapìâ, 2019, 138, 104266.	2.2	7

#	Article	IF	CITATIONS
19	A Pt(IV) prodrug of kiteplatin with the bone-targeting pyrophosphate ligand. Inorganica Chimica Acta, 2019, 494, 98-104.	2.4	6
20	Syntheses and Biological Studies of Cu(II) Complexes Bearing Bis(pyrazol-1-yl)- and Bis(triazol-1-yl)-acetato Heteroscorpionate Ligands. Molecules, 2019, 24, 1761.	3.8	18
21	Phosphine–copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I. , 2019, , 61-82.		6
22	Phosphine copper(I) complexes as anticancer agents: biological characterization. Part II. , 2019, , 83-107.		8
23	Phytochemical Fingerprinting and In Vitro Bioassays of the Ethnomedicinal Fern Tectaria coadunata (J.) Tj ETQq1	1 9.78431	4 ggBT /Over
24	A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring. RSC Advances, 2019, 9, 32448-32452.	3.6	7
25	Triple action Pt(<scp>iv</scp>) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chemical Science, 2018, 9, 4299-4307.	7.4	121
26	Synthesis, characterization and cytotoxic activity of novel copper(II) complexes with aroylhydrazone derivatives of 2-Oxo-1,2-dihydrobenzo[h]quinoline-3-carbaldehyde. Journal of Inorganic Biochemistry, 2018, 182, 18-28.	3.5	41
27	Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes. Neurotoxicity Research, 2018, 34, 93-108.	2.7	10
28	Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors. Free Radical Biology and Medicine, 2018, 127, 62-79.	2.9	97
29	The first waterâ€soluble copper(I) complexes bearing sulfonated imidazole―and benzimidazoleâ€derived Nâ€heterocyclic carbenes: Synthesis and anticancer studies. Applied Organometallic Chemistry, 2018, 32, e4185.	3.5	23
30	A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 3775.	4.1	19
31	Syntheses and biological studies of nitroimidazole conjugated heteroscorpionate ligands and related Cu(I) and Cu(II) complexes. Journal of Inorganic Biochemistry, 2018, 187, 33-40.	3.5	22
32	Dual-acting antitumor Pt(<scp>iv</scp>) prodrugs of kiteplatin with dichloroacetate axial ligands. Dalton Transactions, 2018, 47, 7144-7158.	3.3	21
33	Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions. International Journal of Molecular Sciences, 2018, 19, 2050.	4.1	15
34	Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(<scp>iv</scp>) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)]. Dalton Transactions, 2017, 46, 7005-7019.	3.3	43
35	Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates. Scientific Reports, 2017, 7, 3751.	3.3	38
36	Tamoxifen-like metallocifens target the thioredoxin system determining mitochondrial impairment leading to apoptosis in Jurkat cells. Metallomics, 2017, 9, 949-959.	2.4	30

#	Article	IF	CITATIONS
37	A Cu(<scp>ii</scp>) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights. Chemical Communications, 2017, 53, 134-137.	4.1	30
38	Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors. Scientific Reports, 2017, 7, 13936.	3.3	45
39	Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. Journal of Inorganic Biochemistry, 2017, 177, 1-7.	3.5	38
40	An unsymmetric cisplatin-based Pt(<scp>iv</scp>) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. Dalton Transactions, 2017, 46, 14174-14185.	3.3	39
41	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie - International Edition, 2017, 56, 11539-11544.	13.8	100
42	A Quadrupleâ€Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angewandte Chemie, 2017, 129, 11697-11702.	2.0	22
43	Exploring the C^N^C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes. Bioorganic and Medicinal Chemistry, 2017, 25, 5452-5460.	3.0	32
44	Encapsulation of lipophilic kiteplatin Pt(<scp>iv</scp>) prodrugs in PLGA-PEG micelles. Dalton Transactions, 2016, 45, 13070-13081.	3.3	27
45	Insights into the cytotoxic activity of the phosphane copper(I) complex [Cu(thp)4][PF6]. Journal of Inorganic Biochemistry, 2016, 165, 80-91.	3.5	38
46	Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Scientific Reports, 2016, 6, 29367.	3.3	56
47	Mitochondrial Thioredoxin System as a Modulator of Cyclophilin D Redox State. Scientific Reports, 2016, 6, 23071.	3.3	46
48	Pt(<scp>iv</scp>) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chemical Science, 2016, 7, 2381-2391.	7.4	155
49	Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands. Journal of Inorganic Biochemistry, 2016, 160, 85-93.	3.5	18
50	Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents. Molecules, 2015, 20, 12732-12756.	3.8	53
51	DNA damage and induction of apoptosis in pancreatic cancer cells by a new dinuclear bis(triazacyclonane) copper complex. Journal of Inorganic Biochemistry, 2015, 145, 101-107.	3.5	35
52	Homoleptic phosphino copper(<scp>i</scp>) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity. Metallomics, 2015, 7, 1497-1507.	2.4	54
53	Glucose-Coated Superparamagnetic Iron Oxide Nanoparticles Prepared by Metal Vapour Synthesis Are Electively Internalized in a Pancreatic Adenocarcinoma Cell Line Expressing GLUT1 Transporter. PLoS ONE, 2015, 10, e0123159.	2.5	28
54	<i>trans</i> , <i>cis</i> , <i>cis</i> ,i>cisâ€Bis(benzoato)dichlorido(cyclohexaneâ€1 <i>R</i> ,2 <i>R</i> â€diamine)platinu a Prodrug Candidate for the Treatment of Oxaliplatinâ€Refractory Colorectal Cancer. ChemMedChem, 2014, 9, 1299-1305.	m(IV): 3.2	22

#	Article	IF	CITATIONS
55	Advances in Copper Complexes as Anticancer Agents. Chemical Reviews, 2014, 114, 815-862.	47.7	1,375
56	<i>In Vitro</i> and <i>in Vivo</i> Anticancer Activity of Copper(I) Complexes with Homoscorpionate Tridentate Tris(pyrazolyl)borate and Auxiliary Monodentate Phosphine Ligands. Journal of Medicinal Chemistry, 2014, 57, 4745-4760.	6.4	100
57	Synthesis and in vitro antitumor activity of water soluble sulfonate- and ester-functionalized silver(I) N-heterocyclic carbene complexes. Journal of Inorganic Biochemistry, 2013, 129, 135-144.	3.5	70
58	Novel Mixed-Ligand Copper(I) Complexes: Role of Diimine Ligands on Cytotoxicity and Genotoxicity. Journal of Medicinal Chemistry, 2013, 56, 7416-7430.	6.4	72
59	Fluorescent silver(i) and gold(i)–N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights. Metallomics, 2013, 5, 1006.	2.4	121
60	Neutral and charged phosphine/scorpionate copper(I) complexes: Effects of ligand assembly on their antiproliferative activity. European Journal of Medicinal Chemistry, 2013, 59, 218-226.	5.5	65
61	Possible Chelating Agents for Iron and Aluminium – 4â€Hydroxyâ€5â€methyl―and 4â€Hydroxyâ€1,5â€dimethylâ€3â€pyridinecarboxylic Acid. European Journal of Inorganic Chemistry, 2013, 2013, 1310-1319.	2.0	8
62	Synthesis and Biological Activity of Ester- and Amide-Functionalized Imidazolium Salts and Related Water-Soluble Coinage Metal N-Heterocyclic Carbene Complexes. Inorganic Chemistry, 2012, 51, 9873-9882.	4.0	93
63	Revisiting [PtCl ₂ (<i>cis</i> -1,4-DACH)]: An Underestimated Antitumor Drug with Potential Application to the Treatment of Oxaliplatin-Refractory Colorectal Cancer. Journal of Medicinal Chemistry, 2012, 55, 7182-7192.	6.4	65
64	A novel copper complex induces paraptosis in colon cancer cellsâ€, <i>via</i> â€,the activation of ER stress signalling. Journal of Cellular and Molecular Medicine, 2012, 16, 142-151.	3.6	128
65	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(iii) compounds studied with combined mass spectrometry and biochemical assays. MedChemComm, 2011, 2, 50-54.	3.4	94
66	Nitroimidazole and glucosamine conjugated heteroscorpionate ligands and related copper(ii) complexes. Syntheses, biological activity and XAS studies. Dalton Transactions, 2011, 40, 9877.	3.3	42
67	Chemistry and Biological Activity of Platinum Amidine Complexes. ChemMedChem, 2011, 6, 1172-1183.	3.2	41
68	In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands. Journal of Inorganic Biochemistry, 2011, 105, 232-240.	3.5	101
69	Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochemical Pharmacology, 2010, 79, 90-101.	4.4	216
70	The relationship between the electrospray ionization behaviour and biological activity of some phosphino Cu(I) complexes. Rapid Communications in Mass Spectrometry, 2010, 24, 1610-1616.	1.5	27
71	A New Class of Antitumor <i>trans</i> -Amine-Amidine-Pt(II) Cationic Complexes: Influence of Chemical Structure and Solvent on in Vitro and in Vivo Tumor Cell Proliferation. Journal of Medicinal Chemistry, 2010, 53, 6210-6227.	6.4	29
72	Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radical Biology and Medicine, 2009, 47, 710-721.	2.9	59

#	Article	IF	CITATIONS
73	Cytotoxicity of cis-platinum(II) cycloaliphatic amidine complexes: Ring size and solvent effects on the biological activity. Journal of Inorganic Biochemistry, 2009, 103, 1113-1119.	3.5	19
74	Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA). Journal of Inorganic Biochemistry, 2009, 103, 1644-1651.	3.5	55
75	Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. Coordination Chemistry Reviews, 2009, 253, 1692-1707.	18.8	513
76	In Vitro Antitumor Activity of the Water Soluble Copper(I) Complexes Bearing the Tris(hydroxymethyl)phosphine Ligand. Journal of Medicinal Chemistry, 2008, 51, 798-808.	6.4	117
77	Cisplatinum and Transplatinum Complexes with Benzyliminoether Ligands; Synthesis, Characterization, Structureâ"Activity Relationships, and In Vitro and In Vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 2007, 50, 4775-4784.	6.4	40
78	Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radical Biology and Medicine, 2007, 42, 872-881.	2.9	367
79	Synthesis, Characterization, and in Vitro Antitumor Properties of Tris(hydroxymethyl)phosphine Copper(I) Complexes Containing the New Bis(1,2,4-triazol-1-yl)acetate Ligand. Journal of Medicinal Chemistry, 2006, 49, 7317-7324.	6.4	115
80	Purification of Mitochondrial Thioredoxin Reductase and Its Involvement in the Redox Regulation of Membrane Permeability. Free Radical Biology and Medicine, 1998, 24, 370-376.	2.9	125